{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"The response rate (RR) is the percentage of patients whose cancer shrinks or disappears after treatment.","groups":[{"description":"Participants who crossed over to active drug after placebo. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG000","title":"Cohort A: Liposarcoma Crossover"},{"description":"Participants who crossed over to active drug after placebo. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off\n\nRegorafenib\n\nRegorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off","id":"OG001","title":"Cohort B: Osteosarcoma Crossover"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who started on placebo then crossed over to active drug.","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Response Rate (RR), Cohorts A and B, After Crossover.","type":"SECONDARY","unitOfMeasure":"Participants"}